These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 2513145

  • 21. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons.
    Kohmura C, Gold HK, Yasuda T, Holt R, Nedelman MA, Guerrero JL, Weisman HF, Collen D.
    Arterioscler Thromb; 1993 Dec; 13(12):1837-42. PubMed ID: 8241105
    [Abstract] [Full Text] [Related]

  • 22. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
    Lynch JJ, Cook JJ, Sitko GR, Holahan MA, Ramjit DR, Mellott MJ, Stranieri MT, Stabilito II, Zhang G, Lynch RJ.
    J Pharmacol Exp Ther; 1995 Jan; 272(1):20-32. PubMed ID: 7815334
    [Abstract] [Full Text] [Related]

  • 23. Thrombolytic therapy: enhancement by platelet and platelet-derived mediator antagonists.
    Willerson JT, Golino P, McNatt J, Eidt J, Yao SK, Buja LM.
    Mol Biol Med; 1991 Apr; 8(2):235-43. PubMed ID: 1806765
    [Abstract] [Full Text] [Related]

  • 24. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D.
    J Am Coll Cardiol; 1990 Sep; 16(3):714-22. PubMed ID: 2117620
    [Abstract] [Full Text] [Related]

  • 25. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ.
    Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
    [Abstract] [Full Text] [Related]

  • 26. Monoclonal antibody [7E3 F(ab')2] prevents arterial but not venous rethrombosis.
    Sudo Y, Kilgore KS, Lucchesi BR.
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):241-50. PubMed ID: 7475049
    [Abstract] [Full Text] [Related]

  • 27. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
    Holahan MA, Mellott MJ, Garsky VM, Shebuski RJ.
    Pharmacology; 1991 Aug; 42(6):340-8. PubMed ID: 1946598
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time.
    Tschopp JF, Driscoll EM, Mu DX, Black SC, Pierschbacher MD, Lucchesi BR.
    Coron Artery Dis; 1993 Sep; 4(9):809-17. PubMed ID: 8287215
    [Abstract] [Full Text] [Related]

  • 31. Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis.
    Werns SW, Rote WE, Davis JH, Guevara T, Lucchesi BR.
    Am Heart J; 1994 Apr; 127(4 Pt 1):727-37. PubMed ID: 8154409
    [Abstract] [Full Text] [Related]

  • 32. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
    Mousa SA, Forsythe MS, Diemer M, Bozarth JM, Reilly TM.
    Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
    Spriggs D, Gold HK, Hashimoto Y, Van Houtte E, Vermylen J, Collen D.
    Thromb Haemost; 1989 Feb 28; 61(1):93-6. PubMed ID: 2501892
    [Abstract] [Full Text] [Related]

  • 37. Inhibitory effect of a novel orally active GP IIb/IIIa inhibitor, SC-54684A on intimal thickening in the guinea pig femoral artery.
    Umemura K, Nishiyama H, Kikuchi S, Kondo K, Nakashima M.
    Thromb Haemost; 1996 Nov 28; 76(5):799-806. PubMed ID: 8950793
    [Abstract] [Full Text] [Related]

  • 38. Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart.
    Mickelson JK, Simpson PJ, Lucchesi BR.
    J Mol Cell Cardiol; 1989 Apr 28; 21(4):393-405. PubMed ID: 2746660
    [Abstract] [Full Text] [Related]

  • 39. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS, Zoldhelyi P, Webster MW, Heras M, Grill DE, Holmes DR, Fuster V, Chesebro JH.
    Circulation; 1996 Feb 15; 93(4):792-9. PubMed ID: 8641009
    [Abstract] [Full Text] [Related]

  • 40. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
    Higo K, Karasawa A, Kubo K.
    Arzneimittelforschung; 1991 Dec 15; 41(12):1251-5. PubMed ID: 1815525
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.